On-treatment PSA kinetics as a potential biomarker: Guiding personalized treatment in metastatic hormone-sensitive ...
In this issue of Med, Bian et al. present a post-hoc analysis of the phase 3 CHART trial investigating rezvilutamide in the metastatic hormone-sensitive prostate cancer setting.1 They show that patients achieving a deep PSA response at six months had …